Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Cash from Financing Activities (2019 - 2025)

Historic Cash from Financing Activities for Revolution Medicines (RVMD) over the last 7 years, with Q3 2025 value amounting to -$1.6 million.

  • Revolution Medicines' Cash from Financing Activities fell 10205.97% to -$1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 2213.15%. This contributed to the annual value of $959.4 million for FY2024, which is 2194.82% down from last year.
  • Revolution Medicines' Cash from Financing Activities amounted to -$1.6 million in Q3 2025, which was down 10205.97% from $256.6 million recorded in Q2 2025.
  • In the past 5 years, Revolution Medicines' Cash from Financing Activities ranged from a high of $873.8 million in Q4 2024 and a low of -$1.6 million during Q3 2025
  • In the last 5 years, Revolution Medicines' Cash from Financing Activities had a median value of $10.7 million in 2021 and averaged $160.0 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first surged by 10619672.13% in 2023, then plummeted by 10205.97% in 2025.
  • Over the past 5 years, Revolution Medicines' Cash from Financing Activities (Quarter) stood at $10.7 million in 2021, then soared by 378.78% to $51.4 million in 2022, then skyrocketed by 1534.16% to $839.4 million in 2023, then grew by 4.1% to $873.8 million in 2024, then crashed by 100.18% to -$1.6 million in 2025.
  • Its last three reported values are -$1.6 million in Q3 2025, $256.6 million for Q2 2025, and $874000.0 during Q1 2025.